Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Different Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo in a Prospective Controlled Dose Finding Phase IIb Trial

NCT05144217 is registered in ClinicalTrials.gov with Prof. Dr. Frank Behrens as lead sponsor.

NCT NCT05144217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05144217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Different Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo in a Prospective Controlled Dose Finding Phase IIb Trial
Lead sponsor
Prof. Dr. Frank Behrens
Phase
Phase 2/3
Overall status
Completed
Start date
June 23, 2021
Completion date
December 15, 2024
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

drug-induced liver injury